1 be a very useful adjunct in the diagnosis of dysgerminomas.

2       The analysis of 21 malignant OGCTs (12 dysgerminomas, 6 endodermal sinus tumors, and 3 mixed GC

3 atogenesis and is expressed in seminomas and dysgerminomas, a subset of human germ cell tumors (GCTs)

4 ations in 54 testicular seminomas, 1 ovarian dysgerminoma and 37 non-seminomatous germ cell tumors (N

5  amplification in the development of ovarian dysgerminoma and the use of Sunitinib, a receptor tyrosi

6  in normal ovarian follicles, and by ovarian dysgerminomas and granulosa cell tumors.

7                Most patients with metastatic dysgerminoma can expect cure with maintenance of normal

8 sphotransferase domain in tumors of seminoma/dysgerminoma differentiation.

9 teratomas, malignant germ cell tumors [GCTs (dysgerminomas, endodermal sinus tumors, and mixed GCTs)]

10     The collected tumor tissues included ten dysgerminomas, five yolk sac tumors, five immature terat

11 eated with BEP chemotherapy for pure ovarian dysgerminoma from January 1984 to January 1998.

12               Compared with yolk sac tumors, dysgerminomas highly express PD-L1 and are associated wi

13 atient apparently developed a second primary dysgerminoma in her remaining ovary after BEP and was cl

14   No KIT mutations were found in the ovarian dysgerminoma or the NSGCTs.

15 re they are termed germinomas, seminomas, or dysgerminomas, respectively.

16 ompared with PD-L1-negative yolk sac tissue, dysgerminomas/seminomas with high PD-L1 expression are a